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ABSTRACT
Objectives Patients who are deteriorating, with
uncertain recovery and with a short prognosis
often have complex needs. The AMBER care
bundle systematically manages these patients by
promoting consistent communication and care
planning. To describe how the AMBER bundle is
applied in a UK hospital. To identify factors
affecting the use of the AMBER bundle in patients
who subsequently died. To gain preliminary data
with regard to potential markers of deterioration in
groups less frequently supported by AMBER
Methods Retrospective review of electronic case
notes for all deaths over 11 months on five
inpatient wards where AMBER was implemented.
Results N=149. Median age 80, IQR 72–87.
Admission diagnoses: cancer (25%), non-cancer
(31%), multimorbidity (44%). 38% were
supported by AMBER. Patients with cancer were
more frequently supported by AMBER (62% vs
30% p<0.001). Illness trajectory was defined a
priori as ‘predictable gradual’ (40%), ‘predictable
rapid’ (22%), ‘unpredictable’ (21%) or ‘sudden
death’ (17%). ‘Predictable gradual’ deterioration
resulted in more frequent support by AMBER
(62% vs 21%, p<0.001). Patients were supported
by AMBER after median 10 days of admission (IQR
5–17 days), and died median 9 days later (IQR
3–15 days). Patients with multimorbidity or
unpredictable deterioration were less frequently
supported by AMBER. Potential markers of
deterioration were acute kidney injury, delirium,
falls and comorbidity.
Conclusions The use of the AMBER care bundle
is affected by illness trajectory and diagnosis.
Future work should clarify predictors of
deterioration in patients with an unpredictable
course.
BACKGROUND
Health needs are often highly complex in
advanced illness.1 Identifying patients who
are deteriorating with uncertain recovery
allows us to support complex needs with
tools such as the AMBER care bundle. The
AMBER care bundle is used in hospital
inpatients who have been identified as
facing uncertain recovery and are at risk of
dying in the next 1–2 months.2 The tool
requires nursing and medical staff to
develop a clear plan for the patient’s
further care, including a decision on escal-
ation of care, and to include the patient
and family in care planning. The patient’s
status is reassessed daily, and communica-
tion with the patient and family is priori-
tised. The AMBER care bundle therefore
provides a systematic approach to man-
aging complex needs and uncertain recov-
ery, and allows patients and medical teams
to be clearer about the aims of treatment,
without limiting its scope.
The AMBER care bundle is a relatively
new intervention and requires evaluation.
As part of this evaluation we should
describe how it is used, and identify
whether patients who could benefit from it
are identified. Here, we describe how the
AMBER care bundle is used in patients
who subsequently die in hospital. Many
patients supported by AMBER survive to
hospital discharge, and we are therefore
describing only one aspect of this tool.
Initially, we observed which patients
were supported by the AMBER bundle,
and factors affecting this. One such
factor is trajectory of illness, a concept
which has been investigated, but is less
well understood in final hospital admis-
sion.3 4 Then we looked for patients who
were not as frequently supported by this
tool to see if there is potential to identify
these patients better. Evaluation of these
aspects of the AMBER care bundle’s use
will help to change practice and improve
care.
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AIM
To describe factors affecting the use of the AMBER
care bundle in patients who die in hospital, particu-
larly the effect of illness trajectory; and to gain prelim-
inary data with regard to patients who deteriorate
unpredictably.
METHODS
Case-note review: We undertook, in a single teaching
hospital, a retrospective case-note review of all patients
who died over an 11 month period in five medical
wards where the AMBER care bundle was implemen-
ted. Two reviewers shared data collection from elec-
tronic case notes, accessed from a National Health
Service (NHS) computer. The reviewers cross-checked
their work to ensure consistency. One reviewer col-
lected further information from the fully computerised
medical records, using an agreed proforma.
Disease categories: Patients were allocated disease
categories based on their main reason for admission.
This was either ‘cancer’, ‘non-cancer’ or ‘multi-
morbidity’ (defined as >two major comorbidities).
Illness trajectories: Based on initial data we defined
trajectories of final illness among patients who died.
These were defined a priori as ‘predictable-gradual’,
‘predictable-rapid’, ‘unpredictable’ and ‘sudden death’
(see figure 1). Categorisation was by two reviewers
based on medical records and disagreements were
resolved by discussion—this method has previously
resulted in good agreement when assessing suitability
for AMBER care bundle at case-note review.5 We also
recorded the length of terminal phase—defined clinic-
ally as the point from which patients consistently dete-
riorated to death.
Specific groups: Some patients had an unpredictable
trajectory with poorly recognised deterioration (group
C, figure 1). We identified potential markers of deteri-
oration in this group. We collected data on variables
that might inform prognosis
Analysis: Data were collated in a spreadsheet and
analysed in SPSS V.19 using descriptive statistics. The
relationships between trajectory of illness, disease cat-
egory, use of the AMBER bundle and length of admis-
sion were investigated using χ2 testing for categorical
data, and Kruskal-Wallis and Mann-Whitney U testing
for continuous data.
Ethics: This project was approved by the authorised
signatory for service evaluation studies at the NHS
Trust concerned.
RESULTS
Our sample of 149 had a median age of 80, IQR 72–87.
Length of stay was median 15 days (IQR 8–25 days,
maximum 278 days), and length of terminal phase was
10 days (IQR 5–17 days, maximum 83 days).
AMBER care bundle: 56/149 (38%) of our sample
were supported by the AMBER care bundle. Median
time in hospital prior to its start was 10 days (IQR
5–17 days) and patients died a median of 9 days (IQR
3–15 days) later; 23/37 (62%) patients with cancer
were supported by the care bundle, which was signifi-
cantly more than the 33/112 (30%) of patients
Figure 1 Illness trajectory definitions.
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without cancer (χ2=13.055, p<0.001). Patients sup-
ported by the care bundle had a longer admission
(U=3581.5, p<0.001) and longer terminal phase
(U=2545.5, p=0.001).
Trajectory of illness: 60/149 (40%) of patients had
predictable-gradual deterioration. Thirty-seven (62%)
of these patients were supported by the AMBER care
bundle. This was more than other trajectories
(χ2=26.346, p<0.001). Predictable-gradual illness
trajectory also resulted in longer admission (H=48.395,
p<0.001) and longer terminal phase (H=68.941,
p<0.001). (See table 1).
Thirty-one patients deteriorated unpredictably. These
patients were less frequently supported by the AMBER
care bundle, and a higher proportion (19, 61%) had
multimorbidity. These patients had a median length of
stay of 12 days (IQR 5–34) before the terminal phase.
Terminal phase lasted median 5 days. We found high
admission rates of acute kidney injury (AKI), delirium
and falls in this population (see table 2).
DISCUSSION
Use of the AMBER care bundle
For the first time we have described how the AMBER
care bundle is used across patient groups in patients
who subsequently die in hospital. We have identified
patient groups which were less frequently supported.
This is important because it increases our understanding
of which patients are reliably identified as deteriorating.
Patients whose deterioration is better understood
are more likely to be supported by the AMBER care
bundle, and two factors affect the understanding of
deterioration. First, recognition of deterioration takes
time; we found that patients who were supported by
the AMBER care bundle were admitted to wards
which used the care bundle for several days before
they were supported by it. The rapidly deteriorating
group of patients may therefore have deteriorated too
quickly to be identified as suitable for AMBER.
Second, the illness trajectory of some conditions, such
as cancer, is better understood than others, and these
patients were more frequently supported by the care
bundle.3 4 Patients with multimorbidity were less fre-
quently cared for by the AMBER care bundle, which
could indicate that they are less easy to identify. This is
important because in an ageing population, the preva-
lence of multimorbidity will increase.13 We need to be
able to identify and support these patients effectively.
Importance of predictability
It is important to know that some patients deteriorate
unpredictably since this is the first step in identifying









Falls/collapse 39% 1.9% 3%6
Delirium 35% 2.4% 20.7%7
Acute kidney injury 29% 7.7% 7.2%8
Admissions in last year mean, median 1.16, 1 – 3.59
Karnofsky performance status mean, median 39, 40 – –
Abnormal physiology* 29% – –
Length of stay (days) Mean, median 34, 17 – 5.3, 110
Charlson comorbidity index11 12 mean, median 2.9, 3† – –
*Defined as local early warning score >2.
†A Charlson score of 3 equates to 19.27% 1-year mortality.
Table 1 description of illness trajectory distribution and relationship to diagnosis, use of AMBER care bundle and length of admission
and terminal phase
Trajectory Overall Predictable gradual Predictable rapid Unpredictable Sudden death
Age. Median (IQR) 80 (72–87) 79 (68–89) 79 (71–84) 82 (70–89) 82 (78–87)
Number (%, 95% CI) 149 (100%) 60 (40%, 32 to 48%) 32 (22%, 15 to 29%) 31 (21%, 15 to 28%) 26 (17%, 12 to 24%)
Supported by AMBER n (%) 56 (38%) 37 (62%) 8 (25%) 8 (26%) 3 (12%)
Length of stay, days
Median (IQR)
15 (8–25) 20 (14–29) 7 (4–10) 17 (10–37) 10 (4–21)
Length of terminal phase, days
Median (IQR)
10 (5–17) 17 (12–26) 6 (3–7) 5 (2–8) <24 h*
Admission problem (%)
Cancer 25 38 28 7 12
Non-cancer 31 20 34 32 50
Comorbidity 44 42 38 61 38
*Patients with sudden death by definition deteriorated over less than 24 hours.
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and supporting them prospectively. In our unpredict-
able group, patients were in hospital for several days
before they deteriorated, and subsequently deterio-
rated rapidly. These patients were supported less fre-
quently by the AMBER care bundle and could have
been better supported had they been identified, and
the care bundle used earlier in the phase where prog-
nosis was uncertain.
There was high prevalence of AKI, delirium and
falls on admission in the unpredictable group. These
were much higher than comparator data sources.
These should be investigated as possible predictors of
deterioration.
Limitations
The AMBER care bundle is a complex intervention
and we present evidence on only one component of
this since we focused only on patients who died. Since
we used mortality data, we cannot comment on the
58% of patients supported by the care bundle who
survived to hospital discharge in this time period.
This was a single site design, and there is evidence
that the AMBER care bundle is used differently in dif-
ferent hospitals. To fully evaluate AMBER, a multisite
design is needed, and this is in development.
The retrospective nature of case-note reviews intrin-
sically limits the relevance of illness trajectory to clin-
ical practice. Further work is needed to assess the
usefulness of allocating illness trajectory prospectively.
Analysis of the unpredictable group was limited by
small subgroup size. Furthermore our case-note
review method is likely to have different sensitivity to
the methods used to estimate prevalence of AKI, delir-
ium and falls in discharge data and the literature. This
difference in data collection methods limits the com-
parison between these sources.
CONCLUSION
We have described the use of the AMBER care bundle
in a hospital population. In those who died, the
AMBER care bundle was more frequently used where
there was more certainty regarding deterioration to
death, compared with those where there was greater
uncertainty. Some groups of patients whom the
AMBER bundle was designed to support (ie, those
with multimorbidity and an unpredictable illness tra-
jectory) were less frequently supported, suggesting
that in this hospital the care bundle is not yet being
used as effectively as hoped. We have suggested
markers which might identify patients who deteriorate
unpredictably, and further investigation of these is
warranted. These findings will be useful to further
development the AMBER care bundle and other tools
for the care of patients with uncertain recovery.
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